TY - JOUR
T1 - Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis
AU - Duffin, Rodger
AU - O'Connor, Richard A.
AU - Crittenden, Siobhan
AU - Forster, Thorsten
AU - Yu, Cunjing
AU - Zheng, Xiaozhong
AU - Smyth, Danielle
AU - Robb, Calum T.
AU - Rossi, Fiona
AU - Skouras, Christos
AU - Tang, Shaohui
AU - Richards, James
AU - Pellicoro, Antonella
AU - Weller, Richard B.
AU - Breyer, Richard M.
AU - Mole, Damian J.
AU - Iredale, John P.
AU - Anderton, Stephen M.
AU - Narumiya, Shuh
AU - Maizels, Rick M.
AU - Ghazal, Peter
AU - Howie, Sarah E.
AU - Rossi, Adriano G.
AU - Yao, Chengcan
PY - 2016/3/18
Y1 - 2016/3/18
N2 - Systemic inflammation, which results from the massive release of proinflammatory molecules into the circulatory system, is a major risk factor for severe illness, but the precise mechanisms underlying its control are not fully understood. We observed that prostaglandin E2 (PGE2), through its receptor EP4, is down-regulated in human systemic inflammatory disease. Mice with reduced PGE2 synthesis develop systemic inflammation, associated with translocation of gut bacteria, which can be prevented by treatment with EP4 agonists. Mechanistically, we demonstrate that PGE2-EP4 signaling acts directly on type 3 innate lymphoid cells (ILCs), promoting their homeostasis and driving them to produce interleukin-22 (IL-22). Disruption of the ILC-IL-22 axis impairs PGE2-mediated inhibition of systemic inflammation. Hence, the ILC-IL-22 axis is essential in protecting against gut barrier dysfunction, enabling PGE2-EP4 signaling to impede systemic inflammation.
AB - Systemic inflammation, which results from the massive release of proinflammatory molecules into the circulatory system, is a major risk factor for severe illness, but the precise mechanisms underlying its control are not fully understood. We observed that prostaglandin E2 (PGE2), through its receptor EP4, is down-regulated in human systemic inflammatory disease. Mice with reduced PGE2 synthesis develop systemic inflammation, associated with translocation of gut bacteria, which can be prevented by treatment with EP4 agonists. Mechanistically, we demonstrate that PGE2-EP4 signaling acts directly on type 3 innate lymphoid cells (ILCs), promoting their homeostasis and driving them to produce interleukin-22 (IL-22). Disruption of the ILC-IL-22 axis impairs PGE2-mediated inhibition of systemic inflammation. Hence, the ILC-IL-22 axis is essential in protecting against gut barrier dysfunction, enabling PGE2-EP4 signaling to impede systemic inflammation.
UR - http://www.scopus.com/inward/record.url?scp=84961801657&partnerID=8YFLogxK
U2 - 10.1126/science.aad9903
DO - 10.1126/science.aad9903
M3 - Article
C2 - 26989254
AN - SCOPUS:84961801657
SN - 0036-8075
VL - 351
SP - 1333
EP - 1338
JO - Science
JF - Science
IS - 6279
ER -